Abstract
The cytoplasmatic tyrosine in kinase c-Src is involved in the regulation of several cell functions including adhesion, invasion, proliferation, survival and angiogenesis. Src activity is strictly regulated in healthy cells, whereas its overexpression or hyperactivation plays a critical role during tumor development. Recently it has been suggested that the oncogenic potential of Src is linked to its role in the activation of key signalling molecules involved in several cell pathways, rather than its direct activity. For all these reasons Src represents a promising therapeutic target for the treatment of tumors. In this article a number of examples of c-Src inhibitors appeared in selected patents from 2006 to early 2011 will be reported, focusing on their chemical features and, whenever possible, on structure- activity relationships and mechanism of action. Examples of type I or II ATP-competitive inhibitors or substrate competitive inhibitors will be presented. The research in this field is very active and will probably lead to the discovery of therapeutically useful compounds, both c-Src selective and multitargeted inhibitors, that acting on different cell pathways could be more effective in blocking cancer development. However, only the results of clinical trials will show in the near future the most promising compounds.
Keywords: Patent, c-Src, inhibitors, tyrosine kinases, cancer, ATP-competitive, substrate-competitive, cytoplasmatic tyrosine, proliferation, angiogenesis
Current Medicinal Chemistry
Title: Src Kinase Inhibitors: An Update on Patented Compounds
Volume: 18 Issue: 33
Author(s): S. Schenone, C. Brullo, F. Musumeci, M. Radi and D. Castagnolo
Affiliation:
Keywords: Patent, c-Src, inhibitors, tyrosine kinases, cancer, ATP-competitive, substrate-competitive, cytoplasmatic tyrosine, proliferation, angiogenesis
Abstract: The cytoplasmatic tyrosine in kinase c-Src is involved in the regulation of several cell functions including adhesion, invasion, proliferation, survival and angiogenesis. Src activity is strictly regulated in healthy cells, whereas its overexpression or hyperactivation plays a critical role during tumor development. Recently it has been suggested that the oncogenic potential of Src is linked to its role in the activation of key signalling molecules involved in several cell pathways, rather than its direct activity. For all these reasons Src represents a promising therapeutic target for the treatment of tumors. In this article a number of examples of c-Src inhibitors appeared in selected patents from 2006 to early 2011 will be reported, focusing on their chemical features and, whenever possible, on structure- activity relationships and mechanism of action. Examples of type I or II ATP-competitive inhibitors or substrate competitive inhibitors will be presented. The research in this field is very active and will probably lead to the discovery of therapeutically useful compounds, both c-Src selective and multitargeted inhibitors, that acting on different cell pathways could be more effective in blocking cancer development. However, only the results of clinical trials will show in the near future the most promising compounds.
Export Options
About this article
Cite this article as:
Schenone S., Brullo C., Musumeci F., Radi M. and Castagnolo D., Src Kinase Inhibitors: An Update on Patented Compounds, Current Medicinal Chemistry 2011; 18 (33) . https://dx.doi.org/10.2174/092986711797636135
DOI https://dx.doi.org/10.2174/092986711797636135 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Markers of Tumor Progression in Melanoma
Current Genomics Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Anti-Angiogenic Agents and Cancer: Current Insights and Future Perspectives
Recent Patents on Anti-Cancer Drug Discovery The Use of Inorganic Compounds in Photodynamic Therapy: Improvements in Methods and Photosensitizer Design
Recent Patents on Nanotechnology Targeted Delivery of Bleomycin: A Comprehensive Anticancer Review
Current Cancer Drug Targets Novel Pentapeptide Activators of Mammalian and Mushroom Tyrosinase
Current Topics in Medicinal Chemistry Beam Commissioning Data Acquisition for the Iris Variable Aperture Collimator of CyberKnife VSI
Neuroscience and Biomedical Engineering (Discontinued) Anti-proliferative Properties of miR-20b and miR-363 from the miR-106a-363 Cluster on Human Carcinoma Cells
MicroRNA Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued) Metastasis-Initiating Cells in Renal Cancer
Current Signal Transduction Therapy The Ubiquitin-Proteasome System (UPS) and the Mechanism of Action of Bortezomib
Current Pharmaceutical Design Cerebral Aneurysm as an Exacerbating Factor in Stroke Pathology and a Therapeutic Target for Neuroprotection
Current Pharmaceutical Design Pollen Diversity, Antiradical and Antibacterial Activity and Phenolic Contents of some Polish Honeys
Current Nutrition & Food Science The Rational Design of Anticancer Platinum Complexes: The Importance of the Structure-Activity Relationship
Current Medicinal Chemistry Epigenetic Effects of Cadmium in Cancer: Focus on Melanoma
Current Genomics The Development of Targeted Therapies for Hepatocellular Cancer
Current Pharmaceutical Design From Bacteria to Antineoplastic: Epothilones A Successful History
Anti-Cancer Agents in Medicinal Chemistry CYP3A4-mediated Pharmacokinetic Interactions in Cancer Therapy
Current Drug Metabolism 2D, 3D, G-QSAR and Docking Studies of Thiazolyl-pyrazoline Analogues as Potent (Epidermal Growth Factor Receptor-tyrosine Kinase) EGFR-TK Inhibitors
Letters in Drug Design & Discovery Advances in Chemotherapy and Targeted Systemic Therapies for Urothelial Cancer
Current Drug Therapy